Based on trademark filings, Azultro was thought to be Allergan’s Oxymetazoline based topical treatment for the red face of rosacea – but we now know that Allergan has chosen Rhofade as their product name. To follow all of the news on Rhofade be sure to check out Rhofade News and Articles.
Recent Rosacea Blog Posts
Allergan has confirmed that their Oxymetazoline based treatment due to be released in 2017 will be known as Rhofade. The brand name was confirmed in Allergan’s presentation to investors – Allergan plc Q2 2016 Earnings Presentation – Investor Relations, via the slide shown above. Business analysts are already commenting on their predictions for Rhofade’s success […]
Rosacea sufferers learnt recently that Allergan’s Oxymetazoline based topical (likely to be called Azultro) has been submitted for FDA approval and could be approved in the first half of 2017. For those wanting to try this claimed gentler-than-Mirvaso treatment for a red face, waiting for another year can seem like an eternity. If you are […]
Allergan today have confirmed that a new drug application for their 1% oxymetazoline hcl cream has been formally lodged with the FDA. The prediction from Allergan is that the approval will come in the first half of 2017. This is the first confirmation that Allergan has settled on a 1% formulation of oxymetazoline hydrochloride, having […]
Two small updates on the progress of topical oxymetazoline (now known as Rhofade) towards being available as another treatment for the redness of rosacea. The update tells us firstly that Allergan’s Oxymetazoline based product is in indeed in the final stages of approval, having completed Phase 3 trials and been submitted to the FDA for […]
Allergan haven’t announced it yet, but it seems pretty clear that they are planning to use the brand name Azultro for their oxymetazoline based treatment for the erythema of rosacea. Azultro started life as V-101 when owned by Vicept Therapeutics. It was renamed as AGN-199201 after Allergan purchased Vicept. Actavis now owns Allergan. I had […]